Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133511 | 0.84 | THRB (0.51) | KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL3145767 | 0.83 | THRA (0.37) | MCHR1KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL4356847 | 0.83 | KDM4E (0.43) | MCHR1KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL4356848 | 0.83 | KDM4E (0.43) | MCHR1KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL3141802 | 0.79 | MAPT (0.38) | MCHR1KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL3131792 | 0.76 | THRB (0.53) | KDM4ECYP2C19CYP3A4HIF1A | |
| SCHEMBL5077546 | 0.74 | KDM4E (0.45) | KDM4ECYP2C19CYP3A4HIF1AMAPT | |
| SCHEMBL5077547 | 0.74 | KDM4E (0.45) | KDM4ECYP2C19CYP3A4HIF1AMAPT | |
| SCHEMBL3130687 | 0.69 | HDAC1 (0.37) | MEN1KMT2A | |
| SCHEMBL3137511 | 0.69 | THRA (0.52) | MCHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | MCHR1 268/4885KDM4E 1562/4885CYP2C19 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.